Buscar en
Revista de Psiquiatría y Salud Mental (English Edition)
Toda la web
Inicio Revista de Psiquiatría y Salud Mental (English Edition) Psychotherapygenetic: Do Genes Influence Psychotherapy Adherence?
Journal Information
Vol. 3. Issue 2.
Pages 68-71 (January 2010)
Share
Share
Download PDF
More article options
Vol. 3. Issue 2.
Pages 68-71 (January 2010)
Brief report
Full text access
Psychotherapygenetic: Do Genes Influence Psychotherapy Adherence?
Psicoterapia genética: ¿influyen los genes en la adherencia a la psicoterapia?
Visits
955
Víctor Péreza,b, Juan Carlos Pascuala,b,
Corresponding author
jpascual@santpau.es

Corresponding author.
, Joaquim Solera,b, Thais Tianaa,b, Anna Cortésa,b, Montserrat Baigeta,b, Ana Martín-Blancoa,b, Enrique Álvareza,b
a Department of Psychiatry, Hospital de la Santa Creu i St. Pau, Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM. Autonomous University of Barcelona, Spain
b Department of Genetics Laboratory, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
This item has received
Article information
Abstract
Objective

There is probably an association between genetic factors, personality traits and response to psychotherapy. We propose the new concept of “psychotherapygenetics” as a strategy to study how genetic factors may influence psychotherapeutic response. The aim was to examine the association between polymorphisms of the serotonin transporter gene (SERT) and the dopamine 4-receptor gene (DRD4) with adherence to psychotherapy.

Method

We performed a prospective study of 110 patients with borderline personality disorder (BPD) who participated in dialectical behavioral therapy (DBT). Three polymorphisms were examined: the 5-HTTLPR and the VNTR on the SERT gene and the 7-repeat allele (D4.7) on the DRD4 gene. The dropout rate and the mean number of sessions attended were used as an adherence index.

Results

The presence of the 12-repeat allele on the VNTR polymorphism of SERT was associated with higher adherence to psychotherapy. There was no significant association between the 5-HTTLPR or D4.7 polymorphisms and adherence.

Conclusions

Our preliminary results show a correlation between certain genetic variations and adherence to DBT in patients with BPD. A “psychotherapygenomics” approach could be useful to study how genetic variables may influence patients’ psychotherapy response.

Keywords:
Borderline personality disorder
Genetics
Psychotherapy
Resumen
Objetivo

Probablemente exista una asociación entre factores genéticos, rasgos de personalidad y respuesta a la psicoterapia. Se propone el nuevo concepto de “psicoterapiagenética” como estrategia para estudiar cómo los factores genéticos pueden influir sobre la respuesta terapéutica. El objetivo fue examinar la asociación entre polimorfismos del gen que codifica al transportador de serotonina (SERT) y el gen que codifica para el receptor de la dopamina D4 (DRD4) con la adherencia a la psicoterapia.

Método

Estudio prospectivo con 110 pacientes diagnosticados de Trastorno Límite de la Personalidad (TLP) que participaron en Terapia Dialéctica-Conductual (TDC). Se examinaron tres polimorfismos: el 5-HTTLPR y el VNTR del gen SERT y la presencia del alelo de 7 repeticiones (D4.7) del gen DRD4. Como medidas de adherencia se usaron la tasa de abandonos y la media de sesiones que realizaron.

Resultados

La presencia del alelo de 12 repeticiones del polimorfismo VNTR del SERT se asoció con una mayor adherencia a la psicoterapia. No se observaron asociaciones significativas entre los polimorfismos 5-HTTLPR o D4.7 y adherencia.

Conclusiones

Nuestros resultados preliminares muestran una correlación entre algunas variaciones genéticas y la adherencia a TDC en pacientes con TLP. La estrategia de “psicoterapiagenética” podría ser útil para estudiar cómo las variables genéticas influyen en la respuesta a la psicoterapia.

Palabras clave:
Trastorno límite de la personalidad
Genética
Psicoterapia
Full text is only aviable in PDF
References
[1.]
M.J. Arranz, J. De Leon.
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Mol Psychiatry, 12 (2007), pp. 707-747
[2.]
C. Holden.
Parsing the genetics of behaviour.
Science, 322 (2008), pp. 892-895
[3.]
H. Steiger, R. Joober, L. Gauvin, et al.
Serotonin-system polymorphisms (5-HTTLPR and -1438G/A) and responses of patients with bulimic syndromes to multimodal treatments.
J Clin Psychiatry, 69 (2008), pp. 1565-1571
[4.]
American Psychiatric Association Practice Guidelines.
Practice guideline for the treatment of patients with borderline personality disorder.
Am J Psychiatry, 158 (2001), pp. 1-52
[5.]
K. Lieb, M. Zanarini, C. Schmahl, M. Linehan, M. Bohus.
Borderline Personality Disorder.
[6.]
J.B. Savitz, R.S. Ramesar.
Genetic variants implicated in personality: a review of the more promising candidates.
Am J Med Genet B Neuropsychiatr Genet, 131 (2004), pp. 20-32
[7.]
J.A. Lieberman, T.S. Stroup, J.P. McEvoy, et al.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
N Eng J Med, 353 (2005), pp. 1209-1223
[8.]
M. Gómez-Beneyto, M. Villar, M. Renovell, F. Pérez, M. Hernández, C. Leal, et al.
The diagnosis of personality disorder with a modified version of the SCID-II in a Spanish clinical sample.
J Personal Disord, 8 (1994), pp. 104-110
[9.]
J. Barrachina, J. Soler, M.J. Campins, A. Tejero, J.C. Pascual, E. Alvarez, et al.
[Validation of a Spanish version of the Diagnostic Interview for Bordelines-Revised (DIB-R)].
Actas Esp Psiquiatr, 32 (2004), pp. 293-298
[10.]
W. Guy.
Assessment manual for psychopharmacology.
US Department of Health, Education, and Welfare, (1976),
[11.]
J. Soler, J.C. Pascual, J. Campins, J. Barrachina, D. Puigdemont, E. Álvarez, et al.
Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.
Am J Psychiatry, 162 (2005), pp. 1221-1224
[12.]
J. Soler, J.C. Pascual, T. Tiana, A. Cebrià, J. Barrachina, M.J. Campins, et al.
Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder. A 3-month randomised controlled clinical trial.
Behav Res Ther, 47 (2009), pp. 353-358
[13.]
A. Heils, A. Teufel, S. Petri, et al.
Allelic Variation of Human Serotonin Transporter Gene Expression.
J Neurochemistry, 66 (1996), pp. 2621-2624
[14.]
H.H. Van Tol, C.M. Wu, H.C. Guan, et al.
Multiple dopamine D4 receptor variants in the human population.
Nature, 358 (1992), pp. 149-152
[15.]
C.R. Cloninger, D.M. Svrakic, T.R. Przybeck.
Psychobiological model of temperament and character.
Arch Gen Psychiatry, 50 (1993), pp. 975-990
[16.]
M. Zuckerman.
Psychobiology of personality.
Cambridge University Press, (1991),
[17.]
X. Ni, K. Chan, N. Bulgin, et al.
Association between serotonin transporter gene and borderline personality disorder.
J Psychiatr Res, 40 (2006), pp. 448-453
Copyright © 2010. SEP y SEPB
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos